News

Sacituzumab govitecan demonstrated a longer PFS and OS than single-agent chemotherapy in patients with metastatic TNBC in a phase 3 clinical trial.
Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.
For patients with relapsed SCLC, second-line, platinum-doublet chemotherapy may be beneficial over non-platinum regimens.
Tazemetostat yielded durable responses and was generally well tolerated in a recent study of heavily pretreated patients with relapse or refractory follicular lymphoma (FL; Lancet Oncol. 2020 Oct 6.…
Blinatumomab leads to an improvement in event-free survival (EFS) when compared to consolidation chemotherapy in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL…
Prognostic biomarker testing rates for patients with CLL and SLL is low, indicating the need for more comprehensible treatment options, according to data presented at the virtual ONS Congress.
The FDA has approved loncastuximab tesirine-lpyl for patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
At the virtual 2021 Great Debates & Updates in Women’s Oncology meeting, Shannon N. Westin, MD, MPH, provided an overview on the current and emerging therapies for platinum-resistant ovarian…
At the Great Debates & Updates in Women’s Oncology meeting, Shanu Modi, MD, provided insight on personalized treatments for HER2+ breast cancer.
Stay in the know.
OncNet Newsletter